Insider trade

Officer sold ~$347K of KRYS shares in the open market

Traded Jun 25, 2026 · Filed Jun 26, 2026

Why it stands out

Krystal Biotech's General Counsel sold $347K of Krystal Biotech shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Officer$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$347,270

Shares × reported transaction price

Timing vs results

39 days before results of Aug 3, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−0.9%	+1.4%	−2.3%
30 days	−3.9%	−1.6%	−2.4%
90 days	−10.9%	+3.3%	−14.2%

Past results only. Not a forecast.

The acquisition and sale of shares of the Company's common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. All transactions contemplated by the plan have been completed, and the plan has terminated in accordance with its terms.

3mo ago

Derivative exercise or conversion — not an open-market buy.

3mo ago

Derivative exercise or conversion — not an open-market buy.

Scheduled in advance4mo ago